Will NHS England Commission Medical Cannabis? The Debate

NHS England Commissioning Medical Cannabis: The Current Debate
The question of whether NHS England should commission medical cannabis more widely remains one of the most contentious issues in modern healthcare policy. Despite rescheduling cannabis as a Schedule 2 controlled drug in 2018, making it legally possible for doctors to prescribe, NHS provision remains extremely limited. This disparity between legal availability and actual commissioning has created significant debate amongst healthcare professionals, patient advocates, and policy makers across the country.

The NICE Barrier: Evidence and Guidelines
One of the most significant obstacles to NHS commissioning of medical cannabis is the position of the National Institute for Health and Care Excellence (NICE). The organisation has maintained a cautious stance, citing insufficient evidence for most conditions. Currently, NICE has produced guidance for only a handful of specific conditions: childhood epilepsy (particularly Dravet syndrome and Lennox-Gastaut syndrome), chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity.

This restrictive evidence framework, whilst intended to protect patients, has created a bottleneck. The evidence bar set by NICE is extraordinarily high, requiring multiple randomised controlled trials and robust long-term safety data. However, conducting such trials for cannabis-based products is complex and costly, partly due to its controlled drug status. This creates a circular problem: without NHS commissioning, funding for trials is limited; without trials, NICE guidance cannot expand.

Critics argue that NICE’s approach doesn’t account for real-world clinical experience from other countries where medical cannabis has been available longer, nor does it adequately consider the experiences of patients currently accessing private treatments or travelling abroad for care.

Integrated Care Systems and Funding Decisions

Responsibility for NHS commissioning has increasingly devolved to Integrated Care Systems (ICSs) across England. This localised approach theoretically allows for tailored healthcare decisions reflecting regional needs. However, it has also created postcode lottery effects regarding medical cannabis access.

Some ICSs have shown greater willingness to commission medical cannabis products for specific patient cohorts, while others refuse entirely. This inconsistency means patients in some parts of England have significantly better access than those elsewhere, despite identical clinical presentations and needs. Financial pressures facing ICSs further complicate matters—medical cannabis products are expensive, and stretched budgets often force difficult prioritisation decisions against other treatments.

The lack of clear national commissioning standards has left ICSs uncertain about their obligations and authority, resulting in defensive decision-making that privileges established treatments regardless of their comparative effectiveness.

Patient Advocacy and Lived Experience

Patient advocacy groups have become increasingly vocal about these barriers. Families with children suffering from intractable epilepsy, adult patients with chronic pain, and those with treatment-resistant conditions report compelling anecdotal evidence of medical cannabis effectiveness. Many have invested significant personal resources in accessing private prescriptions or travelling internationally for treatment.

Patient advocates argue that the current system prioritises theoretical evidence hierarchies over demonstrated clinical benefit and patient autonomy. They emphasise that many established NHS treatments lack the same level of rigorous evidence as expected for cannabis, yet remain widely commissioned. This perceived double standard fuels frustration and demands for more equitable assessment.

What Would Need to Change

Meaningful progress requires several interconnected changes. First, NICE must develop more pragmatic, proportionate guidance that incorporates real-world evidence, clinical experience, and patient perspectives alongside randomised trials. Their framework should acknowledge the particular challenges of cannabis research whilst maintaining appropriate safety standards.

Second, NHS England should establish clear national commissioning standards for medical cannabis, creating consistency across ICSs. This would reduce postcode lottery effects and provide healthcare professionals with definitive guidance.

Third, adequate funding must be allocated for high-quality research into medical cannabis, recognising that improved evidence requires investment. This could involve establishing dedicated research centres and streamlining regulatory pathways for cannabis trials.

Finally, patient voices must be systematically incorporated into policy development. Those with lived experience of medical cannabis use should help shape commissioning frameworks and evidence standards.

Without these changes, the current situation—where medical cannabis remains legal to prescribe but practically unavailable on the NHS for most patients—will persist, forcing individuals toward private treatment or travelling abroad.

Integrated Care Systems and Funding Decisions

Patient Advocacy and Lived Experience

What Would Need to Change

Further Reading